Product image of Metformax Combi (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Metformax Combi

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Metformax Combi (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredient in Metformax Combi, is a Biguanide; DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to control blood glucose levels.

GNH India supplies Metformax Combi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Teva Pharmaceuticals Polska Sp. Z O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metformax Combi is used in the treatment of type 2 diabetes mellitus and related hyperglycaemic conditions.

  • Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels.
  • Adults with inadequate glycaemic control on metformin alone: provides additional glucose‑lowering effect.
  • Patients requiring combination therapy to simplify regimen: combines two mechanisms in a single tablet for improved adherence.

How It Works

  • Metformax Combi combines metformin, which reduces hepatic glucose production and enhances peripheral insulin sensitivity, with sitagliptin, a DPP‑4 inhibitor that prolongs the activity of incretin hormones (GLP‑1 and GIP). This dual action increases insulin secretion in a glucose‑dependent manner and suppresses glucagon release, resulting in improved overall glycaemic control.

Side Effects

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Diarrhoea: loose stools, usually transient.
  • Abdominal discomfort: cramping or pain.
  • Headache: mild tension‑type headache.
  • Upper respiratory tract infection: cold‑like symptoms.
  • Hypoglycaemia (when used with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects

  • Lactic acidosis: rare but potentially fatal metabolic disturbance.
  • Severe skin reactions: such as Stevens‑Johnson syndrome.
  • Pancreatitis: inflammation of the pancreas.
  • Hepatic failure: impaired liver function.
  • Severe hypoglycaemia: especially with concomitant insulin.
  • Anaphylactic reactions: rare allergic responses.

Precautions & Warnings

Metformax Combi should be used with caution in specific clinical situations.

  • Renal function: assess eGFR before initiating and monitor periodically.
  • Hepatic impairment: avoid or use with close monitoring.
  • Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia.
  • Pregnancy: safety not established; discuss risks with a healthcare provider.
  • Drug interactions: review all concomitant medications for potential interactions.
  • Store at ambient temperature: keep below 25°C, in the original pack, protect from moisture.

Avoid Interactions

Metformax Combi may interact with several medicines; monitoring is essential.

Major Interactions (Avoid)

  • Concomitant insulin or sulfonylureas: increased risk of hypoglycaemia.
  • Renal toxic agents (e.g., iodinated contrast): may worsen renal function and raise metformin levels.
  • Cimetidine: can increase metformin plasma concentrations.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may mask symptoms of hypoglycaemia.
  • Diuretics: can affect renal clearance of metformin.
  • Alcohol: may heighten the risk of lactic acidosis.

Frequently Asked Questions

Metformax Combi is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus, especially when monotherapy with metformin does not achieve target levels. It combines two mechanisms to lower fasting and post‑prandial glucose.

Metformin Hydrochloride reduces hepatic glucose production and increases peripheral insulin sensitivity, allowing cells to take up glucose more efficiently. This action helps lower overall blood sugar without causing insulin release.

The specific dose of Metformax Combi is determined by the prescribing clinician based on the patient’s individual medical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Metformax Combi in pregnancy or while breastfeeding has not been fully established. Healthcare providers will weigh potential benefits against risks and may recommend alternative treatments if necessary.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Metformax Combi offers a fixed‑dose combination of metformin and sitagliptin, providing both insulin‑sensitising and incretin‑enhancing effects in one tablet. This can simplify regimens compared with taking two separate agents, while delivering comparable glycaemic efficacy to other combination therapies.

Metformax Combi should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Metformax Combi is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal condition, and severe hypoglycaemia when combined with insulin or sulfonylureas. Patients should be aware of symptoms such as rapid breathing, muscle pain, or extreme fatigue and seek medical attention promptly.

Metformax Combi is contraindicated in patients with severe renal impairment, known hypersensitivity to metformin or sitagliptin, and those with a history of lactic acidosis. It should also be avoided in individuals with acute or chronic metabolic acidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT